BofA expects Medtronic’s pipeline development to see it continue to surpass organic growth expectations as in the previous four quarters.

Ventas (NYSE:VTR) issued a 2025 FFO guidance range with a midpoint that's slightly below the average analyst estimate, turned in a better-than-expected Q4 earnings and revenue, and increased its ...